{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:18:17Z","timestamp":1769253497091,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Development Organization for Frontier Medical Education and Therapeutics in Japan","award":["DOFMET-08"],"award-info":[{"award-number":["DOFMET-08"]}]},{"name":"Development Organization for Frontier Medical Education and Therapeutics in Japan","award":["DOFMET-08"],"award-info":[{"award-number":["DOFMET-08"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H21-3rd Comprehensive 10\u2010year Strategy for Cancer Control-010"],"award-info":[{"award-number":["H21-3rd Comprehensive 10\u2010year Strategy for Cancer Control-010"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)"],"award-info":[{"award-number":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)"],"award-info":[{"award-number":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)\u201d"],"award-info":[{"award-number":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)\u201d"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)\u201d"],"award-info":[{"award-number":["University Reform Action Plan \u201cGunma University Initiative for Advanced Research (GIAR)\u201d"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["Promotion Plan for the Platform of Human Resource Development for Cancer"],"award-info":[{"award-number":["Promotion Plan for the Platform of Human Resource Development for Cancer"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["the Fostering Health Professionals for Changing Needs of Cancer"],"award-info":[{"award-number":["the Fostering Health Professionals for Changing Needs of Cancer"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["New Paradigms \u2013 Establishing Center for Fostering Medical Researchers of the Future Programs"],"award-info":[{"award-number":["New Paradigms \u2013 Establishing Center for Fostering Medical Researchers of the Future Programs"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10147-024-02552-w","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T05:01:45Z","timestamp":1716181305000},"page":"1334-1346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models"],"prefix":"10.1007","volume":"29","author":[{"given":"Reika","family":"Kawabata-Iwakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Colinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9731-7183","authenticated-orcid":false,"given":"Masahiko","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"4","key":"2552_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE et al (2018) Ovarian cancer statistics. CA Cancer J Clin 68(4):284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA Cancer J Clin"},{"issue":"9951","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384(9951):1376\u20131388. https:\/\/doi.org\/10.1016\/S0140-6736(13)62146-7","journal-title":"Lancet"},{"key":"2552_CR3","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S (2022) Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 33:100629. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629","journal-title":"Cancer Treat Res Commun."},{"issue":"6","key":"2552_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41416-020-0734-9","volume":"122","author":"K Hasegawa","year":"2020","unstructured":"Hasegawa K, Shimada M, Takeuchi S et al (2020) A phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer. Br J Cancer 122(6):766\u2013770. https:\/\/doi.org\/10.1038\/s41416-020-0734-9","journal-title":"Br J Cancer"},{"key":"2552_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200225","author":"S Nagao","year":"2023","unstructured":"Nagao S, Fujiwara K, Yamamoto K et al (2023) Intraperitoneal carboplatin for ovarian cancer- a phase 2\/3 trial. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2200225","journal-title":"NEJM Evid"},{"key":"2552_CR6","doi-asserted-by":"publisher","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, et al. (2023) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial Lancet Oncol. 24(10):1109\u20131118, https:\/\/doi.org\/10.1016\/S1470-2045(23)00396-0.","DOI":"10.1016\/S1470-2045(23)00396-0"},{"issue":"3","key":"2552_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10147-003-0318-8","volume":"8","author":"R Medeiros","year":"2003","unstructured":"Medeiros R, Pereira D, Afonso N et al (2003) Platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8(3):156\u2013161. https:\/\/doi.org\/10.1007\/s10147-003-0318-8","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1535-7163.MCT-05-0408","volume":"5","author":"M Komatsu","year":"2006","unstructured":"Komatsu M, Hiyama K, Tanimoto K et al (2006) Prediction of individual response to platinum\/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther 5(3):767\u2013775. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0408","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2552_CR9","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-05-2715","volume":"12","author":"G Ferrandina","year":"2006","unstructured":"Ferrandina G, Zannoni GF, Martinelli E et al (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12(9):2774\u20132779. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2715","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2552_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2006.09.006","volume":"61","author":"J Spratlin","year":"2007","unstructured":"Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61(3):222\u2013229. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.09.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"2552_CR11","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","volume":"68","author":"T Bonome","year":"2008","unstructured":"Bonome T, Levine DA, Shih J et al (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68(13):5478\u20135486. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6595","journal-title":"Cancer Res"},{"issue":"7","key":"2552_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e32832e0ed7","volume":"19","author":"S Marsh","year":"2009","unstructured":"Marsh S, McLeod H, Dolan E et al (2009) Platinum pathway. Pharmacogenet Genomics 19(7):563\u2013564. https:\/\/doi.org\/10.1097\/FPC.0b013e32832e0ed7","journal-title":"Pharmacogenet Genomics"},{"issue":"7353","key":"2552_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network (2011) Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma Nature. 474(7353):609\u2013615. https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Integrated genomic analyses of ovarian carcinoma Nature."},{"issue":"11","key":"2552_CR14","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1158\/1078-0432.CCR-12-0056","volume":"18","author":"JP Gillet","year":"2012","unstructured":"Gillet JP, Calcagno AM, Varma S et al (2012) Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 18(11):3197\u20133206. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0056","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2552_CR15","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1158\/0008-5472.CAN-14-0186","volume":"74","author":"JG Bosquet","year":"2014","unstructured":"Bosquet JG, Marchion DC, Chon H et al (2014) Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. Cancer Res 74(14):3902\u20133912. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0186","journal-title":"Cancer Res"},{"issue":"1","key":"2552_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2016.02.027","volume":"141","author":"R Murakami","year":"2016","unstructured":"Murakami R, Matsumura N, Brown JB et al (2016) Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol Oncol 141(1):49\u201356. https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.027","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2552_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J et al (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321\u201337.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035","journal-title":"Cell"},{"issue":"1","key":"2552_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1158\/1078-0432.CCR-19-1741","volume":"26","author":"F Heitz","year":"2020","unstructured":"Heitz F, Kommoss S, Tourani R et al (2020) Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer. Clin Cancer Res 26(1):213\u2013219. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1741","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2552_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.12669\/pjms.343.14911","volume":"34","author":"A Zehra","year":"2018","unstructured":"Zehra A, Zehra S, Ismail M et al (2018) Glutathione S-transferase M1 and T1 gene deletions and susceptibility to acute lymphoblastic leukemia (ALL) in adults. Pak J Med Sci 34(3):666\u2013670. https:\/\/doi.org\/10.12669\/pjms.343.14911","journal-title":"Pak J Med Sci"},{"key":"2552_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103558","volume":"71","author":"G Wu","year":"2021","unstructured":"Wu G, Peng H, Tang M et al (2021) ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine 71:103558. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103558","journal-title":"EBioMedicine"},{"issue":"11","key":"2552_CR21","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1111\/cas.15137","volume":"112","author":"H Yu","year":"2021","unstructured":"Yu H, Wang H, Qie A et al (2021) FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect. Cancer Sci 112(11):4655\u20134668. https:\/\/doi.org\/10.1111\/cas.15137","journal-title":"Cancer Sci"},{"issue":"1","key":"2552_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13048-021-00831-y","volume":"14","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Cao S, Zhuang C et al (2021) ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 14(1):80. https:\/\/doi.org\/10.1186\/s13048-021-00831-y","journal-title":"J Ovarian Res"},{"key":"2552_CR23","unstructured":"Yamamoto Y. Komatsu M, Fumoto S, et al. Selection of novel maker genes that predict a response to paclitaxel and carboplatin (TC) therapy in ovarian cancer. Cancer Res. 2009 May; 69(9_Supplement), 892. (2009 AACR Annual Meeting Abstract #892)"},{"issue":"34","key":"2552_CR24","doi-asserted-by":"publisher","first-page":"35737","DOI":"10.18632\/oncotarget.5927","volume":"6","author":"C Mehner","year":"2015","unstructured":"Mehner C, Oberg AL, Kalli KR et al (2015) Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget 6(34):35737\u201335754. https:\/\/doi.org\/10.18632\/oncotarget.5927","journal-title":"Oncotarget"},{"issue":"42","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1038\/s41388-020-01451-4","volume":"39","author":"C Mehner","year":"2020","unstructured":"Mehner C, Miller E, Hockla A et al (2020) Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene 39(42):6606\u20136618. https:\/\/doi.org\/10.1038\/s41388-020-01451-4","journal-title":"Oncogene"},{"issue":"8","key":"2552_CR26","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.3390\/ijms22083814","volume":"22","author":"T-C Lin","year":"2021","unstructured":"Lin T-C (2021) Functional roles of SPINK1 in cancers. Int J Mol Sci 22(8):3814. https:\/\/doi.org\/10.3390\/ijms22083814","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2552_CR27","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1038\/s41467-018-06860-4","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen F, Long Q, Fu D et al (2018) Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nat Commun 9(1):4315. https:\/\/doi.org\/10.1038\/s41467-018-06860-4","journal-title":"Nat Commun"},{"key":"2552_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.833741","volume":"12","author":"C Liao","year":"2022","unstructured":"Liao C, Wang Q, An J et al (2022) SPINKs in tumors: potential therapeutic targets. Front Oncol 12:833741. https:\/\/doi.org\/10.3389\/fonc.2022.833741","journal-title":"Front Oncol"},{"issue":"6","key":"2552_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/genes11060679","volume":"11","author":"E Cecchin","year":"2020","unstructured":"Cecchin E, Stocco G (2020) Pharmacogenomics and personalized medicine. Genes (Basel) 11(6):679. https:\/\/doi.org\/10.3390\/genes11060679","journal-title":"Genes (Basel)"},{"key":"2552_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-pharmtox-030920-025745","volume":"61","author":"WC Chang","year":"2021","unstructured":"Chang WC, Tanoshima R, Ross CJD et al (2021) Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu Rev Pharmacol Toxicol 61:65\u201384. https:\/\/doi.org\/10.1146\/annurev-pharmtox-030920-025745","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"17","key":"2552_CR31","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","volume":"42","author":"TM Sissung","year":"2006","unstructured":"Sissung TM, Mross K, Steinberg SM et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17):2893\u20132896. https:\/\/doi.org\/10.1016\/j.ejca.2006.06.017","journal-title":"Eur J Cancer"},{"issue":"11","key":"2552_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.5414\/cpp48729","volume":"48","author":"M Inada","year":"2010","unstructured":"Inada M, Sato M, Morita S et al (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48(11):729\u2013734. https:\/\/doi.org\/10.5414\/cpp48729","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"2552_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","volume":"166","author":"H Zhang","year":"2016","unstructured":"Zhang H, Liu T, Zhang Z et al (2016) Integrated Proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166(3):755\u2013765. https:\/\/doi.org\/10.1016\/j.cell.2016.05.069","journal-title":"Cell"},{"issue":"1","key":"2552_CR34","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.1038\/s41598-022-14592-1","volume":"12","author":"A Bhardwaj","year":"2022","unstructured":"Bhardwaj A, Josse C, Van Daele D et al (2022) Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Sci Rep 12(1):11027. https:\/\/doi.org\/10.1038\/s41598-022-14592-1","journal-title":"Sci Rep"},{"issue":"6","key":"2552_CR35","doi-asserted-by":"publisher","first-page":"8891","DOI":"10.3892\/ol.2018.8500","volume":"15","author":"J Gong","year":"2018","unstructured":"Gong J, Zhou Y, Liu D et al (2018) F-box proteins involved in cancer-associated drug resistance. Oncol Lett 15(6):8891\u20138900. https:\/\/doi.org\/10.3892\/ol.2018.8500","journal-title":"Oncol Lett"},{"key":"2552_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4818651","author":"Y Xiang","year":"2022","unstructured":"Xiang Y, Wang W, Gu J et al (2022) Circular RNA VANGL1 facilitates migration and invasion of papillary thyroid cancer by modulating the miR-194\/ZEB1\/EMT axis. J Oncol. https:\/\/doi.org\/10.1155\/2022\/4818651","journal-title":"J Oncol"},{"issue":"11","key":"2552_CR37","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1158\/0008-5472.CAN-19-2852","volume":"80","author":"J Xie","year":"2020","unstructured":"Xie J, Ye J, Cai Z et al (2020) GPD1 Enhances the anticancer effects of metformin by synergistically increasing total cellular Glycerol-3-phosphate. Cancer Res 80(11):2150\u20132162. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2852","journal-title":"Cancer Res"},{"issue":"1","key":"2552_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-022-01312-5","volume":"15","author":"W Wenlong Zhang","year":"2022","unstructured":"Wenlong Zhang W, He X, Yin H et al (2022) Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis. J Hematol Oncol 15(1):93. https:\/\/doi.org\/10.1186\/s13045-022-01312-5","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2552_CR39","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1038\/s41467-021-24495-w","volume":"12","author":"CW Garvie","year":"2021","unstructured":"Garvie CW, Wu X, Papanastasiou M et al (2021) Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun 12(1):4375. https:\/\/doi.org\/10.1038\/s41467-021-24495-w","journal-title":"Nat Commun"},{"issue":"3","key":"2552_CR40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1535-7163.MCT-18-1233","volume":"19","author":"N Hao","year":"2020","unstructured":"Hao N, Shen W, Du R et al (2020) Phosphodiesterase 3A represents a therapeutic target that drives stem cell-like property and metastasis in breast cancer. Mol Cancer Ther 19(3):868\u2013881. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1233","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2552_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nchembio.1984","volume":"12","author":"L de Waal","year":"2016","unstructured":"de Waal L, Lewis TA, Rees MG et al (2016) Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol 12(2):102\u2013108. https:\/\/doi.org\/10.1038\/nchembio.1984","journal-title":"Nat Chem Biol"},{"key":"2552_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","volume":"170","author":"H Koepsell","year":"2017","unstructured":"Koepsell H (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 170:148\u2013165. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.10.017","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2552_CR43","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00404-011-2166-5","volume":"285","author":"B Lai","year":"2012","unstructured":"Lai B, Xiao Y, Pu H et al (2012) Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 285(5):1455\u20131461. https:\/\/doi.org\/10.1007\/s00404-011-2166-5","journal-title":"Arch Gynecol Obstet"},{"issue":"16","key":"2552_CR44","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","volume":"37","author":"JL Walker","year":"2019","unstructured":"Walker JL, Brady MF, Wenzel L et al (2019) Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study. J Clin Oncol 37(16):1380\u20131390. https:\/\/doi.org\/10.1200\/JCO.18.01568","journal-title":"J Clin Oncol"},{"issue":"21","key":"2552_CR45","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","volume":"27","author":"DR Gandara","year":"2009","unstructured":"Gandara DR, Kawaguchi T, Crowley J et al (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27(21):3540\u20133546. https:\/\/doi.org\/10.1200\/JCO.2008.20.8793","journal-title":"J Clin Oncol"},{"issue":"19","key":"2552_CR46","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1158\/1078-0432.CCR-15-0133","volume":"21","author":"M Komatsu","year":"2015","unstructured":"Komatsu M, Wheeler HE, Chung S et al (2015) Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 21(19):4337\u20134346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0133","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02552-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:03:20Z","timestamp":1724720600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02552-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02552-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}